Close Menu
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Mount Sinai nurses approve new contract ending strike at its NYC hospitals

February 11, 2026

xAI lays out interplanetary ambitions in public all-hands

February 11, 2026

In one of strongest endorsements from Trump admin, Dr. Oz says get measles vaccine

February 11, 2026
Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
Home » Former FDA vaccine chief Peter Marks joins Eli Lilly
Health

Former FDA vaccine chief Peter Marks joins Eli Lilly

IQ TIMES MEDIABy IQ TIMES MEDIAJuly 1, 2007No Comments1 Min Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


(Reuters) -Peter Marks, the former top vaccine regulator who was ousted from the U.S. Food and Drug Administration earlier this year, has joined Eli Lilly, the drugmaker told Reuters on Tuesday.

Marks will oversee molecule discovery and infectious diseases at Lilly Research Laboratories.

“Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our work in emerging areas,” the company told Reuters.

Marks, who played a key role in U.S. President Donald Trump’s first term in developing COVID-19 vaccines, resigned in March after being forced out by U.S. Health Secretary Robert F. Kennedy Jr.

Shares of U.S. drugmakers fell, when reports on Marks’ ouster from the FDA first came out.

As director of the FDA’s Center for Biologics Evaluation and Research, Marks had publicly supported programs that expedited the development of rare disease treatments and gene therapies during his tenure.

STAT News first reported on the development.

(Reporting by Siddhi Mahatole and Sneha S K in Bengaluru; Editing by Shailesh Kuber)



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
IQ TIMES MEDIA
  • Website

Related Posts

Mount Sinai nurses approve new contract ending strike at its NYC hospitals

February 11, 2026

In one of strongest endorsements from Trump admin, Dr. Oz says get measles vaccine

February 11, 2026

James Van Der Beek’s death at 48 puts spotlight on colorectal cancer, young people

February 11, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Yale suspends professor from teaching while reviewing his correspondence with Epstein

February 11, 2026

Gov. Gretchen Whitmer signs classroom smartphone ban for Michigan schools

February 11, 2026

Suspect in Canada school shooting is identified as 18-year-old

February 11, 2026

Gunman apprehended in southern Thailand after holding students and teachers hostage in school

February 11, 2026
Education

Yale suspends professor from teaching while reviewing his correspondence with Epstein

By IQ TIMES MEDIAFebruary 11, 20260

Yale University says a prominent computer science professor will not teach classes while it reviews…

Gov. Gretchen Whitmer signs classroom smartphone ban for Michigan schools

February 11, 2026

Suspect in Canada school shooting is identified as 18-year-old

February 11, 2026

Gunman apprehended in southern Thailand after holding students and teachers hostage in school

February 11, 2026
IQ Times Media – Smart News for a Smarter You
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 iqtimes. Designed by iqtimes.

Type above and press Enter to search. Press Esc to cancel.